Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity

Désirée Bonci, Maria Musumeci, Valeria Coppola, Antonio Addario, Concetta Conticello, Michael Hahne, Massimo Gulisano, Francesco Grignani, and Ruggero De Maria

1Dept. of Hematology, Oncology and Molecular Medicine, Istituto Superiore Sanità, Rome, Italy; 2Mediterranean Institute of Oncology, Catania, Italy; 3Institut de Génétique Moléculaire de Montpellier, France; 4IOM Ricerca, Catania, Italy; 5Patologia Generale, Dipartimento di Medicina Clinica e Sperimentale, Perugia University, Policlinico Monteluce, Perugia, Italy


Online Supplementary Figure S1. APRIL expression and targeting in AML cells. (A) Flow cytometry analysis of AML blasts of M3 and M5 subtypes labeled with anti-APRIL antibody as compared to isotype control staining. One sample of two for each AML subtype is shown. (B) M2 blasts were treated with 5 µg TACI-Fc and 5 µg BCMA-Fc (BCMA/TACI-Fc) or 10 µg Fn14-Fc recombinant soluble receptors and stained after 24h with annexin-V/7AAD. Data are mean ± s.d of three independent experiments in triplicate.